The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
DiaMedica said it plans to launch the trial later in 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Subscribe To Our Newsletter & Stay Updated